Jaffetilchin Investment Partners LLC Purchases New Stake in IQVIA Holdings Inc. (NYSE:IQV)

Jaffetilchin Investment Partners LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 7,598 shares of the medical research company’s stock, valued at approximately $1,493,000.

A number of other institutional investors have also modified their holdings of IQV. Pine Valley Investments Ltd Liability Co raised its holdings in IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after buying an additional 50 shares in the last quarter. Howard Capital Management Inc. raised its stake in shares of IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after acquiring an additional 54 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of IQVIA by 1.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after purchasing an additional 56 shares during the period. Cypress Wealth Services LLC grew its stake in IQVIA by 4.8% in the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock valued at $244,000 after buying an additional 57 shares during the last quarter. Finally, Harbor Investment Advisory LLC lifted its position in IQVIA by 4.7% during the 4th quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company’s stock worth $253,000 after acquiring an additional 58 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Citigroup dropped their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Mizuho dropped their price target on IQVIA from $242.00 to $210.00 and set an “outperform” rating on the stock in a research report on Wednesday. Robert W. Baird reduced their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Morgan Stanley upped their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Finally, Barclays restated an “equal weight” rating and issued a $170.00 price target (down from $235.00) on shares of IQVIA in a research report on Thursday. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $241.50.

IQVIA Stock Performance

Shares of IQV opened at $145.40 on Friday. The firm has a fifty day simple moving average of $182.32 and a 200 day simple moving average of $199.64. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $25.64 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.